#3743
The need of centralisation for small intestinal neuroendocrine tumor surgery – A cohort study from the GTE-Endocan-RENATEN Network, the CentralChirSINET study
Introduction:
The concept of surgical centralization is more and more generalized for specific surgical procedure. Small intestinal (SI) neuroendocrine tumor (NET) surgical resection is well standardized and is the cornerstone of the curative care.
Conference:
Presenting Author:
Walter T
Authors:
Kalifi M,
Lardière-Deguelte S,
Faron M,
Afchain P,
de Mestier L,
Keywords:
Small intestine,
surgery,
neuroendocrine tumor,
centralization,
#3710
Morphological response on mesenteric mass of small intestinal neuroendocrine tumors treated by 177Lu-DOTATATE: MESENLUTH – A GTE-ENDOCAN study
Introduction:
Small intestinal neuroendocrine tumors (SI-NETs) often metastasize, especially to mesenteric lymph nodes, which are frequently affected by fibrosis reactions due to local serotonin secretion. Peptide receptor radionuclide therapy (PRRT) with177Lu-Dotatate has shown its efficacy in the treatment of progressive SI-NETs.
Conference:
Presenting Author:
Walter T
Authors:
Al Mansour L,
de Mestier L,
Haissaguerre M,
Afchain P,
Hadoux J,
Keywords:
neuroendocrine tumor,
mesenteric mass,
objective response,
177Lu-DOTATATE,
#2730
FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling
Introduction:
Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Hadoux J
Authors:
Hadoux J,
Afchain P,
Walter T,
Tougeron D,
Hautefeuille V,
Keywords:
neuroendocrine carcinoma,
gastroenteropancreatic,
chemotherapy,
FOLFIRINOX,
RB,
#501
FOLFOX Regimen for Clinically Aggressive Neuroendocrine Tumors: About one Case
Introduction:
The treatment for progressive metastatic well-differentiated pancreatic neuroendocrine tumors is based on adriamycin and streptozotocin chemotherapy, which achieves more than 60% tumor regression. However, severe adverse effects are common.
Conference:
9th Annual ENETSConcerence (2012)
Presenting Author:
Authors:
Bengrine-Lefevre L,
Marijon H,
Afchain P,
Tournigand C,
De Gramont A,
Keywords:
well-differentiated endocrine tumor,
FOLFOX,
thrombotic microangiopathy,
